Overall Survival and Local Control of Hepatic Metastatic Lesions Treated with Stereotactic Body Radiotherapy
Abstract:
Background: Although surgery remains the standard of treatment, Stereotactic Body Radiotherapy (SBRT) is an effective and safe alternative for the management of liver oligometastases. However, it is a technique that is little available in Mexico and requires strict patient selection. Objective: Determine the local control (LC) and overall survival (OS) rate in patients treated with hepatic SBRT from 2017 to 2022. Methods: A retrospective review was performed from January 2017 to August 2022 of the 68 SBRT cases identified. Eleven patients were included in the analysis with: 1-5 metastases, unresectable, maximum diameter of 6 cm in single lesion or ≤10 cm in combination, oligometastatic or oligo progressive disease, adequate liver function (Child Pugh A-B), life expectancy > 6 months and KPS 80-100. Results: 11 patients with 19 hepatic metastases were included, with an average age of 66 years old. Median follow-up was 13 months. The mean number of lesions per patient was 2 (1-3) with a mean PTV of 45.5cc. The most commonly used scheme was 50 Gy in 5 sessions of 10 Gy each, with a median BED of 87.3 Gy. OS at 1 and 2 years was 75%. LC at 1 and 2 years was 83% and 42%, respectively
